Enanta Pharmaceuticals (FRA:9EP) EBIT per Share : €-4.63 (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals EBIT per Share?

Enanta Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2024 was €-1.13. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €-4.63.

During the past 3 years, the average EBIT per Share Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Enanta Pharmaceuticals's EBIT per Share or its related term are showing as below:

FRA:9EP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -53.1 Med: -1.9 Max: 23.4
Current: -1.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Enanta Pharmaceuticals was 23.40% per year. The lowest was -53.10% per year. And the median was -1.90% per year.

FRA:9EP's 3-Year EBIT Growth Rate is ranked worse than
56.4% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs FRA:9EP: -1.90

Enanta Pharmaceuticals's EBIT for the three months ended in Sep. 2024 was €-23.97 Mil.

Enanta Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Enanta Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals EBIT per Share Chart

Enanta Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

EBIT per Share

Get a 7-Day Free Trial

-1.77

-4.53

-5.99

-5.62

-4.55

Enanta Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-1.17	-1.33	-1.26	-0.91	-1.13

Enanta Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Enanta Pharmaceuticals's EBIT per Share for the fiscal year that ended in Sep. 2024 is calculated as

	EBIT per Share		(A: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-96.27	/	21.157
=	-4.55

Enanta Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-23.971	/	21.193
=	-1.13

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.63

Enanta Pharmaceuticals (FRA:9EP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Enanta Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ENTA:USA

Address

4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines